To evaluate the feasibility, safety, and early oncologic response of tumor-infiltrating lymphocyte (TIL) therapy in a patient with well-controlled HIV and metastatic melanoma, highlighting the significance of this population in clinical trials.
Key Findings:
TIL therapy was tolerated with expected toxicities, including grade 1 cytokine release syndrome and grade 3 hypotension.
Imaging at day 44 showed a partial response with decreased pulmonary metastases and stabilization of axillary disease.
Progression of disease was observed by day 86.
CD4 counts fluctuated, but virologic suppression was restored by day 100.
Interpretation:
This case suggests that TIL therapy can be safely administered to patients with well-controlled HIV, demonstrating manageable toxicity and early signs of efficacy, which may inform future research directions.
Limitations:
Single case report limits generalizability and may introduce biases.
Lack of long-term follow-up data on oncologic outcomes.
Conclusion:
The findings highlight the importance of including individuals with HIV in cellular therapy trials to better understand safety and treatment dynamics, emphasizing the need for further studies to validate these findings.
